December 3, 2014

Biocept Appoints Experienced Physician as Medical Director

Veena Singh, MD, FCAP, FACMG Brings Years of Medical Experience to Biocept Team

SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Veena Singh, MD, FCAP, FCAMG has joined the Company as Senior Vice President and Senior Medical Director.

Dr. Singh brings to Biocept years of experience in the diagnostic laboratory industry, previously serving as Medical Director for bioTheranostics, a molecular oncology diagnostics company. During Dr. Singh's tenure at bioTheranostics, the clinical laboratory underwent a significant expansion in both the number and complexity of molecular diagnostic assays of solid tumors utilizing multiple methodologies and platforms including Next Generation Sequencing, RT-PCR and FISH. In addition, she brings a wealth of experience in the field of regulatory compliance issues (FDA, IVDMIA and Companion Diagnostics) and reimbursement.

Prior to bioTheranostics, Dr. Singh completed a Molecular Genetic Pathology fellowship at Cedars Sinai Medical Center in Los Angeles and an Anatomic and Clinical Pathology Residency at the University of California, San Diego. Dr. Singh is board certified in Anatomic and Clinical Pathology as well as Molecular Genetic Pathology.

"I am excited to join the Biocept team, as I have had a personal interest for quite some time in furthering progress with blood based biomarker testing - or, the liquid biopsy. There is a true unmet medical need for patients in situations where-in a surgical biopsy is not possible due to technical reasons or patient performance status issues that could result in a potentially adverse outcome. Molecular biomarker profiling performed on a simple blood draw affords prognostic information, as well as therapeutic and monitoring options," said Dr. Singh.

Michael W. Nall, President and CEO of Biocept, said, "Veena's experience in validating and launching assays in a CLIA lab setting, as well as knowledge of biomarkers under development in research and pharma, will be invaluable for us as we rapidly expand our diagnostic offerings. We are encouraged that our core technology and robust pipeline of tests continue to attract experienced industry leaders like Dr. Singh to our team at Biocept."

Dr. Singh received her medical degree from the University of Transkei in South Africa, her native country. She holds laboratory director licenses for CAP, CLIA and numerous states including New York.

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, California, is a commercial stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BR™ test for breast cancer and OncoCEE-LU ™ for lung cancer and plans to introduce additional biomarker tests for breast, lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to medical trends, expansion of offerings and anticipated product introductions, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings, including without limitation our need to grow our business and our operations, our need for capital, and the effects of reimbursement limitations and other health care statutory and regulatory initiatives. The effects of such risks and uncertainties could cause actual results to differ materially from the

forward-looking statements contained in this release. Readers are advised to review our filings with the Securities and Exchange Commission, which can be accessed over the Internet at the SEC's website located at www.sec.gov

CONTACT: Investor Contact:

The Ruth Group

David Burke/Lee Roth

(646) 536-7009 / (646) 536-7012

dburke@theruthgroup.com/lroth@theruthgroup.com

Media Contact:

The Ruth Group

Melanie Sollid-Penton

(646) 536-7023

msollid@theruthgroup.com

Biocept
Completing the Answer™

Source: Biocept, Inc.